{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:55:41Z","timestamp":1792032941264,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Venetoclax, a selective BCL2 inhibitor, is extensively utilized in clinical settings for the treatment of acute myeloid leukemia (AML). However, its efficacy is often compromised by the development of drug resistance. Hence, identification of potential venetoclax combination treatment strategies is imperative to overcome this acquired resistance. In this study, we discovered that inhibition of METTL3 can synergistically enhance the anti-leukemic efficacy of venetoclax, and is capable of overcoming venetoclax resistance in in vivo experiments and various venetoclax resistance models. Mechanistic study revealed that STM2457 augmented venetoclax activity by downregulating MCL1 and MYC, thereby increasing apoptosis in leukemia cells induced by venetoclax. Further investigation demonstrated that STM2457 promotes the ubiquitination and subsequent protein degradation of MCL1 primarily through pharmaceutically targeting METTL3. Moreover, through molecular docking-based virtual screening, we identified isoliquiritigenin as a potential novel small molecule natural product targeting METTL3, which exhibited potential effects as an anti-leukemic agent.<\/jats:p>","DOI":"10.1038\/s41419-025-07560-w","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T04:49:40Z","timestamp":1743742180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeting METTL3 mitigates venetoclax resistance via proteasome-mediated modulation of MCL1 in acute myeloid leukemia"],"prefix":"10.1038","volume":"16","author":[{"given":"Chang-qing","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-hua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-fei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7829-2547","authenticated-orcid":false,"given":"Qing-song","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-287X","authenticated-orcid":false,"given":"Jian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"7560_CR1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD Dinardo","year":"2023","unstructured":"Dinardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073\u201386.","journal-title":"Lancet"},{"key":"7560_CR2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cpt.1962","volume":"108","author":"N Khanal","year":"2020","unstructured":"Khanal N, Upadhyay BS, Bhatt VR. Novel treatment paradigms in acute myeloid leukemia. Clin Pharm Ther. 2020;108:506\u201314.","journal-title":"Clin Pharm Ther"},{"key":"7560_CR3","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-019-0764-8","volume":"21","author":"M Cerrano","year":"2019","unstructured":"Cerrano M, Itzykson R. New treatment options for acute myeloid leukemia in 2019. Curr Oncol Rep. 2019;21:16.","journal-title":"Curr Oncol Rep"},{"key":"7560_CR4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"key":"7560_CR5","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, Dinardo CD, Short NJ, Borthakur G, et al. De novo acute myeloid leukemia: a population-based study of outcome in the united states based on the surveillance, epidemiology, and end results (seer) database, 1980 to 2017. Cancer. 2021;127:2049\u201361.","journal-title":"Cancer"},{"key":"7560_CR6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, Kohnke T, Stafford M, Bottomly D, Thomas R, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1:826\u201339.","journal-title":"Nat Cancer"},{"key":"7560_CR7","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/sj.leu.2401573","volume":"13","author":"M Andreeff","year":"1999","unstructured":"Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, et al. Expression of bcl-2-related genes in normal and aml progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881\u201392.","journal-title":"Leukemia"},{"key":"7560_CR8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective bcl-2 inhibition by abt-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362\u201375.","journal-title":"Cancer Discov"},{"key":"7560_CR9","unstructured":"Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not apl) (2023). Zhonghua Xue Ye Xue Za Zhi. 2023;44:705\u201312."},{"key":"7560_CR10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase ii study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov"},{"key":"7560_CR11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"7560_CR12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD Dinardo","year":"2018","unstructured":"Dinardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the bcl2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93:401\u20137.","journal-title":"Am J Hematol"},{"key":"7560_CR13","volume":"40","author":"H Wang","year":"2023","unstructured":"Wang H, Zhou J, Ma X, Jiao C, Chen E, Wu Z, et al. Dexamethasone enhances venetoclax-induced apoptosis in acute myeloid leukemia cells. Med Oncol. 2023;40:193.","journal-title":"Med Oncol"},{"key":"7560_CR14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using bh3-mimetic drugs. Nat Rev Cancer. 2022;22:45\u201364.","journal-title":"Nat Rev Cancer"},{"key":"7560_CR15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD Dinardo","year":"2020","unstructured":"Dinardo CD, Tiong IS, Quaglieri A, Macraild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with aml. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"7560_CR16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nature18298","volume":"534","author":"X Wang","year":"2016","unstructured":"Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, et al. Structural basis of n(6)-adenosine methylation by the mettl3-mettl14 complex. Nature. 2016;534:575\u20138.","journal-title":"Nature"},{"key":"7560_CR17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature24678","volume":"552","author":"I Barbieri","year":"2017","unstructured":"Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millan-Zambrano G, Robson SC, et al. Promoter-bound mettl3 maintains myeloid leukaemia by m(6)a-dependent translation control. Nature. 2017;552:126\u201331.","journal-title":"Nature"},{"key":"7560_CR18","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm.4416","volume":"23","author":"LP Vu","year":"2017","unstructured":"Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, et al. The n(6)-methyladenosine (m(6)a)-forming enzyme mettl3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23:1369\u201376.","journal-title":"Nat Med"},{"key":"7560_CR19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, et al. Small-molecule inhibition of mettl3 as a strategy against myeloid leukaemia. Nature. 2021;593:597\u2013601.","journal-title":"Nature"},{"key":"7560_CR20","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41375-022-01696-w","volume":"36","author":"M Li","year":"2022","unstructured":"Li M, Ye J, Xia Y, Li M, Li G, Hu X, et al. Mettl3 mediates chemoresistance by enhancing aml homing and engraftment via itga4. Leukemia. 2022;36:2586\u201395.","journal-title":"Leukemia"},{"key":"7560_CR21","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1016\/j.apsb.2023.05.026","volume":"13","author":"C Hu","year":"2023","unstructured":"Hu C, Shen L, Zou F, Wu Y, Wang B, Wang A, et al. Predicting and overcoming resistance to cdk9 inhibitors for cancer therapy. Acta Pharm Sin B. 2023;13:3694\u2013707.","journal-title":"Acta Pharm Sin B"},{"key":"7560_CR22","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Autodock4 and autodocktools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785\u201391.","journal-title":"J Comput Chem"},{"key":"7560_CR23","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. Synergyfinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u201343.","journal-title":"Nucleic Acids Res"},{"key":"7560_CR24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of ras\/mapk pathway confers mcl-1 mediated acquired resistance to bcl-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7:51.","journal-title":"Signal Transduct Target Ther"},{"key":"7560_CR25","doi-asserted-by":"crossref","first-page":"h1436","DOI":"10.1126\/sciadv.adh1436","volume":"9","author":"Y Nishida","year":"2023","unstructured":"Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, et al. Enhanced tp53 reactivation disrupts myc transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023;9:h1436.","journal-title":"Sci Adv"},{"key":"7560_CR26","doi-asserted-by":"crossref","first-page":"D485","DOI":"10.1093\/nar\/gku1007","volume":"43","author":"DV Veres","year":"2015","unstructured":"Veres DV, Gyurko DM, Thaler B, Szalay KZ, Fazekas D, Korcsmaros T, et al. Comppi: a cellular compartment-specific database for protein-protein interaction network analysis. Nucleic Acids Res. 2015;43:D485\u201393.","journal-title":"Nucleic Acids Res"},{"key":"7560_CR27","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Xie P, Lu L, Wang J, Diao L, Liu Z, et al. An integrated bioinformatics platform for investigating the human e3 ubiquitin ligase-substrate interaction network. Nat Commun. 2017;8:347.","journal-title":"Nat Commun"},{"key":"7560_CR28","volume":"17","author":"CH Yeh","year":"2018","unstructured":"Yeh CH, Bellon M, Nicot C. Fbxw7: a critical tumor suppressor of human cancers. Mol Cancer. 2018;17:115.","journal-title":"Mol Cancer"},{"key":"7560_CR29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13046-021-01880-3","volume":"40","author":"Y Wu","year":"2021","unstructured":"Wu Y, Chang N, Zhang Y, Zhang X, Xu L, Che Y, et al. Mettl3-mediated m(6)a mrna modification of fbxw7 suppresses lung adenocarcinoma. J Exp Clin Cancer Res. 2021;40:90.","journal-title":"J Exp Clin Cancer Res"},{"key":"7560_CR30","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06810-7","volume":"15","author":"GO Nwosu","year":"2024","unstructured":"Nwosu GO, Ross DM, Powell JA, Pitson SM. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis. 2024;15. 413.","journal-title":"Cell Death Dis"},{"key":"7560_CR31","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021;106:894\u20138.","journal-title":"Haematologica"},{"key":"7560_CR32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","volume":"20","author":"S Zaccara","year":"2019","unstructured":"Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mrna methylation. Nat Rev Mol Cell Biol. 2019;20:608\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7560_CR33","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. Mcl-1 and bcl-xl-dependent resistance to the bcl-2 inhibitor abt-199 can be overcome by preventing pi3k\/akt\/mtor activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.","journal-title":"Cell Death Dis"},{"key":"7560_CR34","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang D. Bcl2 and mcl1 inhibitors for hematologic malignancies. Blood. 2021;138:1120\u201336.","journal-title":"Blood"},{"key":"7560_CR35","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"},{"key":"7560_CR36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature09732","volume":"471","author":"H Inuzuka","year":"2011","unstructured":"Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, et al. Scf(fbw7) regulates cellular apoptosis by targeting mcl1 for ubiquitylation and destruction. Nature. 2011;471:104\u20139.","journal-title":"Nature"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07560-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07560-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07560-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T04:50:51Z","timestamp":1743742251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07560-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7560"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07560-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Ethics Committee of the First Affiliated Hospital of Anhui Medical University allowed this research (Approval Number: PJ 2024-09-47). Patients signed the written informed consents. All animals were housed in a specific pathogen-free facility and used according to the animal care regulations of Anhui Medical University. The serial number of the ethical approval for animal experiments is LLSC20232152.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"233"}}